TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient management.

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The tool is less apt to overestimate ASCVD risk than the pooled cohort equations and in turn could reduce overtreatment.

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

With both new and revised measures, the document’s authors aim to provide clinicians usable advice in a digestible format.

It’s not as “perfect as they are selling it,” but it does avoid the more catastrophic complications of thermal ablation, says ...

Cath labs need to be redesigned so that operators aren’t at risk for future injury, even if it requires some hospital ...